Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: Can the fracture risk assessment tool identify those at greatest risk?

Journal of Infectious Diseases

Volumn 211, Issue 3, 2015, Pages 374-382

  Gill, Upkar S ^a   Zissimopoulos, Alexandra ^b   Al Shamma, Safa ^b   Burke, Katherine ^b   McPhail, Mark J W ^c   Barr, David A ^d   Kallis, Yiannis N ^b   Marley, Richard T C ^b   Kooner, Paul ^b   Foster, Graham R ^a   Kennedy, Patrick T F ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

bone mineral density; chronic hepatitis B; DEXA; FRAX; tenofovir

Indexed keywords

ENTECAVIR; PEGINTERFERON; TENOFOVIR DISOPROXIL; ADENINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BONE DENSITY; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE RISK ASSESSMENT TOOL; HEPATITIS B; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; OSTEOPENIA; OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SMOKING; ANALOGS AND DERIVATIVES; CROSS-SECTIONAL STUDY; DRUG EFFECTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; MIDDLE AGED; PROCEDURES; RISK;

ADENINE; ADULT; BODY MASS INDEX; BONE DENSITY; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; RISK; RISK ASSESSMENT;

EID: 84922569770     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu471     Document Type: Article

References (41)

1. Papatheodoridis G, Buti M, Cornberg M, et al. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2012; 57:167-85.
2. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. AASLD practice guidelines. Hepatology 2009; 50:1-36.
3. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373:582-92.
4. Wong V, Chan H. Chronic hepatitis B: A treatment update. Semin Liver Dis 2013; 33:122-9.
5. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open label follow-up study. Lancet 2013; 381:468-75.
6. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir dis-oporoxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21:1273-81.
7. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of teno-fovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
8. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-60.
9. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49:S185-95.
10. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-601.
11. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus the tenofovir-emtricitabine in HIV-infected adults: 48 week results from the ASSERT study. Clin Infect Dis 2010; 51:963-72.
12. Perrot S, Aslangul E, Szwebel T, Caillat-Vigneron N, Le Jeunne C. Bone pain due to fractures revealing osteomalacia related to tenofovir induced proximal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol 2009; 15:72-4.
13. Brim NM, CU-Uvin S, Hu SL, O'Bell JW. Bone disease and pathologic fractures in a patient with tenofovir induced Fanconi syndrome. AIDS Read 2007; 17:322-8.
14. Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6:341-6.
15. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009; 10:482-7.
16. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiviral agents. AIDS 2012; 26:825-31.
17. Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009; 200:1746-54.
18. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, Man-sky KC. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun 2010; 394:48-53.
19. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Mansky KC. Tenofovir-associated bone density loss. Ther Clin Risk Manag 2010; 6:41-7.
20. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in tenofovir pre-exposure prophylaxis randomized clinical trials in San Francisco. PLoS One 2011; 6:e23688.
21. FRAX WHO Fracture Risk Assessment Tool. World Health Organization Collaborating Centre for Metabolic Bone Diseases. Sheffield, UK: University of Sheffield. http://www.shef.ac.uk/FRAX. Accessed 9 April 2014.
22. Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005; 11:1842-7.
23. Fux CA, Rauch A, Simcock M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort study. Antivir Ther 2008; 13:1077-82.
24. Fung S, Kwan P, Fabri M, et al. Randomized comparison of Tenofovir Disoproxil Fumarate vs. Emtricitabine and Tenofovir Disoproxil Fuma-rate in patients with Lamivudine-resistance Chronic Hepatitis B. Gas-troenterology 2014; 146:980-8.
25. Eckstein F, Lochmuller EM, Lill CA, et al. Bone strength at clinically relevant sites displays substantial heterogeneity and is best predicted from site-specific bone densitometry. J Bone Miner Res 2002; 17: 162-71.
26. Collier J. Bone disorders in chronic liver disease. Hepatology 2007; 46:1271-8.
27. Collier J, Ninkovic M, Comstom JE. Guidelines on the management of osteoporosis associated chronic liver disease. Gut 2002; 50:i1-9.
28. Kasonde M, Niska R, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomized trial of pre-expo-sure prophylaxis with Tenofovir-Emtricitabine or placebo in Botswana. PLoS One 2014; 9:e90111.
29. Byrne DD, Newcomb CW, Carbonari DM, et al. Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. J Hepatol 2014; 61:210-8.
30. Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to en-tecavir is associated with better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013; 62:760-5.
31. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58:98-107.
32. Reijnders JG, Perquim ML, Zhang N, Hansen BE, Janssen HL. Nucleos (t)ide analogues only induce temporary hepatitis B e-antigen serocon-version in most patients with chronic hepatitis B. Gastroenterology 2010; 139:491-8.
33. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011; 204:415-8.
34. Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic HBV infections. Gut 2012; 61:333-6.
35. Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int 2011; 31:111-6.
36. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139:1218-29.
37. Murray KF, Szenborn L, Wysocki J, et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012; 56:2018-26.
38. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998; 28:695-9.
39. Christodoulou S, Goula T, Ververidis A, Drosos G. Vitamin D and bone disease. Biomed Res Int 2013; 2013:396541.
40. Patel JV, Chackathayil J, Hughes EA, Webster C, Lip GY, Gill PS. Vitamin D deficiency amongst ethnic minority groups in the UK: a cross sectional study. Int J Cardiol 2013; 167:2172-6.
41. Haskelberg H, Cordery DV, Amin J, et al. HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS One 2014; 9:e93333.